Novel action beta-blockers combine many different pharmacological effects. The espindolol exhibits effects through β and central 5-HT1α receptors to demonstrate pro-anabolic, anti-catabolic, and appetite-stimulating actions. In the ACT-ONE trial, espindolol reversed weight loss and improved handgrip strength in patients with cachexia due to non-small cell lung cancer or colorectal cancer. With this trial, another frontier of cachexia management is in sight. Nonetheless, more efficacy and safety data is needed before new therapeutic indications for novel action beta-blockers can be endorsed.
ACT-ONE - ACTION at last on cancer cachexia by adapting a novel action beta-blocker / Lainscak, Mitja; Laviano, Alessandro. - In: JOURNAL OF CACHEXIA, SARCOPENIA AND MUSCLE. - ISSN 2190-5991. - 7:4(2016), pp. 400-402. [10.1002/jcsm.12136]
ACT-ONE - ACTION at last on cancer cachexia by adapting a novel action beta-blocker
LAVIANO, Alessandro
2016
Abstract
Novel action beta-blockers combine many different pharmacological effects. The espindolol exhibits effects through β and central 5-HT1α receptors to demonstrate pro-anabolic, anti-catabolic, and appetite-stimulating actions. In the ACT-ONE trial, espindolol reversed weight loss and improved handgrip strength in patients with cachexia due to non-small cell lung cancer or colorectal cancer. With this trial, another frontier of cachexia management is in sight. Nonetheless, more efficacy and safety data is needed before new therapeutic indications for novel action beta-blockers can be endorsed.| File | Dimensione | Formato | |
|---|---|---|---|
|
Lainscak_ACT-ONE-action_2016.pdf
accesso aperto
Tipologia:
Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
241.21 kB
Formato
Adobe PDF
|
241.21 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
